Joseph A Kaufman

Array ( [id] => 17867377 [patent_doc_number] => 20220290113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 17/285440 [patent_app_country] => US [patent_app_date] => 2019-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33271 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15404045 [patent_doc_number] => 20200022344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => HUMANIZED IL-4 AND IL-4Ra ANIMALS [patent_app_type] => utility [patent_app_number] => 16/594537 [patent_app_country] => US [patent_app_date] => 2019-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16919 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16594537 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16267160 [patent_doc_number] => 20200268647 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => METHOD OF ENHANCING DELIVERY OF THERAPEUTIC COMPOUNDS TO THE EYE [patent_app_type] => utility [patent_app_number] => 16/593302 [patent_app_country] => US [patent_app_date] => 2019-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9395 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16593302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17095481 [patent_doc_number] => 20210283272 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => GENE THERAPY FOR TREATING PROPIONIC ACIDEMIA [patent_app_type] => utility [patent_app_number] => 17/278847 [patent_app_country] => US [patent_app_date] => 2019-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -128 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278847 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16086815 [patent_doc_number] => 20200197394 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => INHIBITION OF SGK1 IN THE TREATMENT OF HEART CONDITIONS [patent_app_type] => utility [patent_app_number] => 16/573333 [patent_app_country] => US [patent_app_date] => 2019-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10829 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16573333 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18254491 [patent_doc_number] => 20230081530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING CANCER USING MRNA THERAPEUTICS [patent_app_type] => utility [patent_app_number] => 17/275832 [patent_app_country] => US [patent_app_date] => 2019-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 108215 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17275832 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156357 [patent_doc_number] => 20210317408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES IN BLOOD OR IN ENRICHED PBMCS [patent_app_type] => utility [patent_app_number] => 17/272631 [patent_app_country] => US [patent_app_date] => 2019-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 93150 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17272631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15646799 [patent_doc_number] => 20200085929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS [patent_app_type] => utility [patent_app_number] => 16/543980 [patent_app_country] => US [patent_app_date] => 2019-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39108 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16543980 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16876880 [patent_doc_number] => 11027000 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-08 [patent_title] => AADC polynucleotides for the treatment of Parkinson's disease [patent_app_type] => utility [patent_app_number] => 16/540375 [patent_app_country] => US [patent_app_date] => 2019-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31912 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 194 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16540375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16885786 [patent_doc_number] => 20210171981 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => VIRAL VECTORS ENCODING CANCER/TESTIS ANTIGENS FOR USE IN A METHOD OF PREVENTION OR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/250561 [patent_app_country] => US [patent_app_date] => 2019-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14008 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17250561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140159 [patent_doc_number] => 20210308170 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => COMPOSITION FOR SUPPRESSION OF AGING, PREVENTION, AMELIORATION, OR TREATMENT OF AN AGE-RELATED DISEASE OR SYMPTOM, OR EXTENSION OF LIFESPAN [patent_app_type] => utility [patent_app_number] => 17/263433 [patent_app_country] => US [patent_app_date] => 2019-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18058 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17263433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15556809 [patent_doc_number] => 20200062816 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => IL-31 Improves Efficacy of Macrophage-Based Adoptive Cell Therapy for Cancer [patent_app_type] => utility [patent_app_number] => 16/516286 [patent_app_country] => US [patent_app_date] => 2019-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7870 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16516286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15405377 [patent_doc_number] => 20200023010 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => Chimeric Antigen Receptors with BCMA Specificity and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/516060 [patent_app_country] => US [patent_app_date] => 2019-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24088 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16516060 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15361063 [patent_doc_number] => 20200016296 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => MENINGEAL REPAIR USING HUMAN UMBILICAL CORD PATCHES [patent_app_type] => utility [patent_app_number] => 16/510818 [patent_app_country] => US [patent_app_date] => 2019-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4566 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16510818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16444891 [patent_doc_number] => 10836803 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-17 [patent_title] => Treatment of retinitis pigmentosa [patent_app_type] => utility [patent_app_number] => 16/505117 [patent_app_country] => US [patent_app_date] => 2019-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 29 [patent_no_of_words] => 28144 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16505117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17185478 [patent_doc_number] => 20210332363 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => BLOOD-BRAIN BARRIER PERMEABLE APTAMER AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/270606 [patent_app_country] => US [patent_app_date] => 2019-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3123 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17270606 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15493325 [patent_doc_number] => 20200046851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => GENE THERAPY FOR RETINITIS PIGMENTOSA [patent_app_type] => utility [patent_app_number] => 16/503091 [patent_app_country] => US [patent_app_date] => 2019-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24060 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16503091 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16204972 [patent_doc_number] => 20200237962 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => Gene Therapy [patent_app_type] => utility [patent_app_number] => 16/457740 [patent_app_country] => US [patent_app_date] => 2019-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19621 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16457740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15173825 [patent_doc_number] => 20190357504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => TRANSITION COW INDEX [patent_app_type] => utility [patent_app_number] => 16/445832 [patent_app_country] => US [patent_app_date] => 2019-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7195 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16445832 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15206469 [patent_doc_number] => 20190365921 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => Method and System of Harvesting Extracellular Vesicles Using Hydrogel Particles for Later Delivery to, and Remodeling of, an Immune System [patent_app_type] => utility [patent_app_number] => 16/430300 [patent_app_country] => US [patent_app_date] => 2019-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8646 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16430300 [rel_patent_id] =>[rel_patent_doc_number] =>)